Lakefront Biotherapeutics

Lakefront Biotherapeutics
FormerlyGalapagos Genomics NV
TypeNaamloze vennootschap
Euronext Amsterdam: GLPG
BEL 20 component
ISINBE0003818359
IndustryPharmaceutical
Founded1999
HeadquartersMechelen, Belgium
Key peopleHenry Gosebruch (CEO)
Jérôme Contamine (Chairman)
ProductsFilgotinib; GLPG1205; GLPG0778
Revenue€288.836 million (2018)
€-29.259 million (2018)
Total assets€1,439.496 million (2018)
Total equity€1,214.249 million (2018)
Number of employees
725 (2018)
Websitelakefrontbio.com

Lakefront Biotherapeutics (formerly known as Galapagos NV and Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.

The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.